Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Multidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications. In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand’s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.

Lab instruments © MORU. Photographer: Direk Limmathurotsakul

7 September 2016, Bangkok (Thailand) – Multidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications.

In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand’s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.

Noting that Thailand’s death rate from multidrug-resistant bacterial infections was high given its smaller population relative to the United States and Europe, the study authors warned that similarly high death rates due to multidrug-resistant bacterial infection were likely to be found in other low and middle-income countries, such as China, India and Indonesia.

“Our study estimates that multidrug-resistant bacterial infections caused an excess of 19,122 deaths in Thailand in 2010. This is large compared to the 23,000 deaths a year estimated in the much more populous USA (316 million population in 2013) and the 25,000 deaths a year in the European Union (500 million population in 2007),” said study senior author Dr. Direk Limmathurotsakul, Head of Microbiology at MORU and Assistant Professor at Mahidol University (Thailand).

“We also show that the proportion of multidrug-resistant bacteria found in patients is increasing and that the burden of antibiotic resistance in Thailand is deteriorating over time,” said Dr. Limmathurotsakul.

“We expect to find similar high rates of multidrug resistant bacterial infections in other low and middle income countries, particularly where broad spectrum antibiotics such as ceftriaxone, ceftazidime and carbapenem are commonly available and used, such as in China, India and Indonesia,” said Dr. Limmathurotsakul.

Antimicrobial resistance is a growing global problem. In low and middle-income countries, bacteria resistant to many commonly used antibiotics are spreading, driven by rising incomes, greater use of affordable antibiotics by both humans and animals, a lack of control of antimicrobial use in hospitals and poor control of over-the-counter sales.

The study authors said that better national estimates on the epidemiology and burden of multidrug resistant bacterial infections could be improved by integrating information from readily available databases in Thailand and other low and middle-income countries.

“The impact of drug-resistant bacterial infections is already considerable – and getting worse. If it’s not to overwhelm Asia’s prosperity and the world’s economic, health and life expectancy gains, we need to take drug resistance seriously and invest heavily in its defeat – now, “ said study collaborator Dr. Nick Day, Director of MORU and Professor at the University of Oxford (UK).

“More systematic studies should be done in low and middle-income countries. We should focus on how to compare the antimicrobial resistance situation in countries where settings, resources for diagnostic tests and laboratory methodologies are different. Finally, we will need to identify where resources and attentions are most needed to effectively fight antimicrobial resistance,” said Prof Day.

Led by researchers at Ministry of Public Health and the Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine and Siriraj Hospital, Mahidol University, in Thailand, and the University of Oxford and University of Cambridge in the United Kingdom, the study was funded by the Ministry of Public Health (Thailand) and the Wellcome Trust (UK).

“This study makes for grim reading, confirming that there were over 19,000 deaths in Thailand due to drug resistance in 2010, a figure which is likely to have risen since. It’s yet another warning to the global community that drug resistant infections are killing people now and we must not wait any longer to take action,” said Dr Jeremy Farrar, Director of the Wellcome Trust.

“Drug resistance is a global issue, which affects all of us whether we live in London or in Bangkok, and all countries need to be part of any solution. We cannot tackle drug resistant infections by isolating our actions to single countries or continents.  At the UN General Assembly later this month we urgently need governments to commit to strategies that combat drug resistance," said Dr Farrar.

Reference:

Lim et al. Epidemiology and Burden of Multidrug-resistant Bacterial Infection in a Developing Country. eLife 6 Sept 2016, http://dx.doi.org/10.7554/eLife.18082

For post publication access to abstract and full text:  http://dx.doi.org/10.7554/eLife.18082

Authors and contributors:

This work was conducted by: Cherry Lim, Emi Takahashi, Maliwan Hongsuwan, Visanu Thamlikitkul, Vanaporn Wuthiekanun, Soawapak Hinjoy, Nicholas Day, Sharon Peacock and Direk Limmathurotsakul.

Similar stories

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.